When Rituximab Isn't Enough: A Case of Rituximab-Resistant Minimal Change Disease (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0710; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She started on a course of 17 weeks of a prednisone taper before starting tacrolimus maintenance therapy August 2022. Obinutuzumab, a newer anti-CD20 monoclonal antibody with higher antibody dependent cellular cytotoxicity and more sustained B cell depletion leading to prolonged medication effects. This case highlights the consideration of obinutuzumab as an alternative therapy in relapsing or treatment-resistant MCD, particularly in patients with contraindications to mainline therapies."
Clinical • Glomerulonephritis • Nephrology • Renal Disease
|
|
Debra S.A Wekesa; Kevin Paul Trappett; Felipe Sebastian Naranjo
|